A new review explores the modern use of hydroxyurea in sickle cell anemia (SCA) in children, highlighting key insights from years of clinical trials and real-world experience. A must-read for anyone involved in SCA care! haematologica.org/article/view/1…

Discontinuation of Len maint. 3 years post autoHCT with sustained BM and imaging MRD -ve status. N=52, 7-year PFS: 90%, 3-year treatment-free survival: 75.8% #mmsm #btsm Thanos Dimopoulos @BloodJournal ashpublications.org/blood/article/…

How I manage major hemorrhage | Blood | American Society of Hematology ashpublications.org/blood/article/…

Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT @BloodJournal ashpublications.org/blood/article/…

Most practice-changing Abstract in #EHA2025, in my opinion, might surprise some. Cyclophosphamide is the new SoC for LGL Leukemia. Kudos to authors for conducting a randomized trial in this ultra rare disease (n=150). library.ehaweb.org/eha/2025/eha20…

🧪 New in Br J Haematol (2025): 🚫 Routine screening for MGUS is contraindicated! ❌ No benefit 😟 Same psychological distress as cancer 🔬 High false positives from κ/λ ratio 💉 Invasive tests done without prior non-invasive checks 📉 No improvement in outcomes from early

📍 Día 2 | Jornadas GATMO Sociedad Argentina de Hematología Cerramos dos días de altísimo nivel académico en trasplante y terapia celular, con gran participación de colegas de toda Argentina y Latinoamérica. #GATMO #SAH #Hematología #Trasplante #TerapiaCelular

🎤 Jornadas GATMO Gracias a los speakers por el altísimo nivel académico y la predisposición para compartir su experiencia y conocimientos. Thank you to all the speakers for the outstanding academic level and their generous willingness to share their experience and knowledge.

Challenges in managing and reporting adverse events in haematological malignancies in low-income and middle-income countries - The Lancet Haematology thelancet.com/journals/lanha…

🎉Finally out🎉 Our study showed value of low dose splenic irradiation and transplantation as part of a curative approach in myelofibrosis with refractory splenomegaly: - significant spleen size reduction - excellent engraftment #mpnsm Transplantation and Cellular Therapy Journal astctjournal.org/article/S2666-…

Here we reviewed molecular advances in MDS with a Latin American Perspective mdpi.com/3340472 #mdpigenes vía Genes MDPI

📢 ¡Ya disponible la edición 2025 del Manual de Recomendaciones GEMFIN en Neoplasias Mieloproliferativas Crónicas Filadelfia Negativas! Una herramienta clave para la práctica clínica. 📘 Descárgalo aquí 👉 manual-gemfin2025.gemfin.org #GEMFIN #MPN #Hematología @sehh_es Hematología y Hemoterapia RYC

🎉Finally out🎉 Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma Now in Blood Journals Portfolio Timely for #EHA2025🥰 #mmsm ashpublications.org/blood/article/…

Presented at #EHA2025: Among patients undergoing stem-cell transplantation from matched related donors, cyclophosphamide plus cyclosporin led to significantly longer GVHD-free, relapse-free survival than standard prophylaxis. Full ALLG BM12 CAST phase 3 trial results:

Excellent presentation by Carmelo Gurnari on the clinico genomic features of therapy-related myeloid neoplasm in 🇮🇹 #EHA2025

Queralt Salas Hospital Clínic to present “HCT #Frailty Scale (HCT-FS) for Assessing Frailty in Allogeneic Hematopoietic Cell Transplant Patients. Results from a Multicenter and Prospective Canadian 🇨🇦 and Spanish 🇪🇸 Initiative” at #EHA2025 #hematology #bmtsm

Ahora en #18ICML, la Dra. Gloria Iacoboni presenta en la sesión “Meet the Professor: T-cell Redirecting Therapies”. Gloria Iacoboni GELTAMO International Conference on Malignant Lymphoma

Big news: Mosun-Pola is superior to chemotherapy for patients with aggressive lymphoma. At International Conference on Malignant Lymphoma, I was honored to present—on behalf of an incredible team of global coauthors—the SUNMO trial: ➡️ First positive Phase III trial in this space without conventional chemotherapy

Patients with TP53-mutated AML/MDS represent a unique and heterogeneous high-risk group that should not be treated as 1 single entity. ow.ly/tEXM50W7tLk #myeloidneoplasia #transplantation #clinicaltrialsandobservations

Top Oncologists from 18th International Conference on Malignant Lymphoma (International Conference on Malignant Lymphoma 2025). Explore data and insights #ICML2025: t.ly/dz8T1 #LARVOL #Hematology #Lymphoma #CancerResearch #Oncology #CancerData #OncologyInsights #18ICML | Graham Collins | Ajay Major, MD, MBA |